Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.
The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07532265 |
A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07530770 |
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis |
RECRUITING | |
| NCT07393984 |
Digital Self-Monitoring in Severe Asthma |
COMPLETED | NA |
| NCT07363642 |
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab |
RECRUITING | PHASE3 |
| NCT07359846 |
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) |
RECRUITING | PHASE3 |
| NCT07343661 |
Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA |
ENROLLING_BY_INVITATION | PHASE4 |
| NCT07328035 |
Remission in Adults With Severe Asthma in Thailand |
RECRUITING | |
| NCT07292805 |
Bronchial Thermoplasty for Adults With Severe Asthma in the Biologic Era |
RECRUITING | NA |
| NCT07276724 |
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) |
RECRUITING | PHASE3 |
| NCT07218172 |
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B) |
COMPLETED |
